Shots: The P-III EXPAND study involves assessing of Mayzent vs PBO in 1,651 patients with SPMS from 31 countries with varying levels of disability (Core Part), EDSS scores of 3·0–6·5, […]readmore
Tags : Secondary Progressive Multiple Sclerosis
Shots: The approval is based on P-III EXPAND study assessing Mayzent vs PBO in 1651 patients with SPMS from 31 countries including 47 participants in Canada with a mean age of […]readmore
Shots: The EC’s approval is based on P-III EXPAND study assessing Mayzent vs PBO in patients with SPMS with active disease defined as patients with relapses in the two years […]readmore
Shots: The approval is based on P-III EXPAND study results assessing Mayzent vs PBO in 1,651 patients with SPMS from 31 countries aged 48yrs. P-III study results: reduction in risk […]readmore